RecruitingPhase IIEN originalGlioma (brain cancer)Other cancers

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E-mutated solid tumors, including anaplastic thyroid, ovarian, cholangiocarcinoma or other rare cancers.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Wiek co najmniej 8 lat, waga co najmniej 25 kg
  • Potwierdzony nowotwór litty lub guz mózgu pierwotny
  • Wykrycie mutacji lub fuzji genu BRAF w biopsji nowotworu lub we krwi
  • Dostępna próbka tkanki archiwalna do badań
  • Zgoda na badania obrazowe (tomografia) przed i podczas leczenia
  • Wcześniejsze leczenie standardowe lub nietolerancja dostępnych terapii
  • Ustąpienie lub zmniejszenie efektów ubocznych z poprzednich terapii

Simplified criteria — AI translation

Trial details

Minimum age
8 Years
Last updated (source)
July 27, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (70)

Precision NextGen Oncology & Research Center

Beverly Hills, United States

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, United States

University of California Los Angeles Rheumatology

Westwood, Los Angeles, United States

Norwalk Hospital

Norwalk, United States

University of Miami Hospital and Clinics

Miami, United States

The John Hopkins Hospital

Baltimore, United States

Maryland Oncology Hematology- Columbia

Rockville, United States

Tufts Medical Center

Boston, United States

Massachusetts General Hospital

Boston, United States

Dana-Farber Cancer Institute

Boston, United States

St. Luke's Hospital

Duluth, United States

Mosaic Life Care at Saint Joseph - Medical Center

Saint Joseph, United States

Nebraska Cancer Specialists - Midwest Cancer Center - Legacy

Omaha, United States

Overlook Medical Center

Summit, United States

Columbia University Irving Medical Center

New York, United States

Memorial Sloan Kettering Cancer Center

New York, United States

Atrium Health Wake Forest Baptist - Comprehensive Cancer Center

Winston-Salem, United States

Nationwide Children's Hospital

Colombus, United States

The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute

Columbus, United States

Taylor Cancer Research Center

Maumee, United States

Toledo Clinic Cancer Center

Toledo, United States

Thomas Jefferson University

Philadelphia, United States

Lifespan Cancer Institute - Rhode Island Hospital

Providence, United States

SCRI - TriStar Medical Group Children's Specialists

Nashville, United States

SCRI Oncology Partners

Nashville, United States

Baylor Scott & White Research Institute

Dallas, United States

University of Texas MD Anderson Cancer Center

Houston, United States

Baylor Scott & White Medical Center

Temple, United States

University of Washington School of Medicine

Seattle, United States

West Virginia University Health Sciences Campus

Morgantown, United States

Newcastle Private Hospital

New Lambton Heights, Australia

Orange Health Service

Orange, Australia

Sydney Children's Hospital Network - Randwick

Randwick, Australia

Flinders Medical Centre

Bedford Park, Australia

The Alfred

Melbourne, Australia

Sunny brook Health Sciences Centre- Bayview Campus

Toronto, Canada

Centre Hospitalier Universitaire Sainte-Justine

Montreal, Canada

Institut Bergonie

Bordeaux, France

Hôpital Nord de Marseille

Marseille, France

Hôpital Morvan

Brest, France

Institut de Cancerologie de l'Ouest- Angers

Angers, France

Gustave Roussy

Villejuif, France

Institut Universitaire du Cancer de Toulouse Oncopole

Toulouse, France

Hôpital Universitaire Pitié Salpêtrière

Paris, France

Universitätsklinikum Heidelberg

Heidelberg, Germany

Krankenhaus Nordwest

Frankfurt am Main, Germany

Charité - Universitätsmedizin Berlin

Berlin, Germany

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST

Meldola, Italy

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

Naples, Italy

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele

Milan, Italy

Istituto Europeo di Oncologia

Milan, Italy

Erasmus Medisch Centrum

Rotterdam, Netherlands

Haukeland Univeritetssjukehus

Bergen, Norway

Oslo Universitetssykehus-Radiumhospitalet

Oslo, Norway

Catholic University of Korea Saint Vincent's Hospital

Suwon, South Korea

Seoul National University Hospital

Suwon, South Korea

Dong-A University Hospital

Pusan, South Korea

Chonnam National University Hwasun Hospital

Hwasun, South Korea

Seoul National University Hospital

Seoul, South Korea

Severance Hospital

Seoul, South Korea

Hospital Clinico Universitarlo de Santiago

Santiago de Compostela, Spain

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital Infantil Universitario Niño Jesús

Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Universitario Virgen del Rocío

Seville, Spain

Hospital Clinico Universitarlo de Valencia

Valencia, Spain

Skånes Universitetssjukhus

Lund, Sweden

Karolinska Universitetssjukhuset

Solna, Sweden

The Christie NHS Foundation Trust

Manchester, United Kingdom

Sarah Cannon Research Institute

London, United Kingdom

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/28/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.